AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.007

+0.00116.67%

Volume:10.72M

Turnover:64.31K

Market Cap:32.98M

PE:-0.39

High:0.007

Open:0.006

Low:0.006

Close:0.006

52wk High:0.040

52wk Low:0.006

Shares:4.71B

Float Shares:3.34B

Volume Ratio:1.17

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-174.71%

ROA:-44.61%

PB:1.34

PE(LYR):-0.39

Loading ...

Overview Company News Filings

Radiopharm Theranostics to Meet With US FDA on Phase 3 Brain Metastases Diagnosis Trial

MT Newswires Live

Radiopharm Theranostics Ltd-Rad to Meet with US FDA to Align on Rad 101 Phase 3 Trial

THOMSON REUTERS

Radiopharm Theranostics Shareholders Vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari Director SPP Allocations at Sept. 11 Meeting

Radiopharm Theranostics Ltd-Share Purchase Plan - NOW Open

THOMSON REUTERS

Radiopharm Theranostics - Plans to Initiate Phase 3 Registrational Trial of Rad 101 in Q4 2026

THOMSON REUTERS

Radiopharm Theranostics - Closing Cash at End of Quarter $4.10 Mln

THOMSON REUTERS

Radiopharm Theranostics Plans Phase 3 Registrational Trial of Imaging Agent Rad101 in Q4 2026

Press Release: Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Approvals

Radiopharm Theranostics Prices Unregistered Warrants in Private Placement at Us$3.79 Per ADS

Radiopharm Theranostics Secures Nearly AU$13 Million Through Dual Institutional Capital Raise

MT Newswires Live

Radiopharm Theranostics Announces Concurrent Us$4.1 Million Registered Direct Offering and up to Additional A$12.7 (us$8.9) Million Australian Placement and Share Purchase Plan

THOMSON REUTERS

Radiopharm Theranostics Calls Extraordinary Shareholder Meeting

Radiopharm Theranostics - Receives Firm Commitments for A$12.5 Mln Capital Raising

THOMSON REUTERS

Radiopharm Theranostics - no Dose-limiting Toxicities Observed with Rad204 in Phase 1 Trial

THOMSON REUTERS

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of Rad204 in Patients with Advanced Solid Tumors Post-immunotherapy

THOMSON REUTERS

Radiopharm Theranostics Partners with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial

Radiopharm Theranostics Announces Positive Phase 2B Trial Results of Rad 101 for Diagnosis of Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics - Rad101 Shows Preliminary 86% Sensitivity in Six-month Follow-up; Specificity Data Expected Q4 2026

THOMSON REUTERS

Radiopharm Theranostics' Phase 2b Trial of Brain Metastases Diagnosis Agent Meets Primary Endpoint

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/RAD.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.007,"timestamp":1790921520000,"preClose":0.006,"halted":0,"volume":10717667,"delay":0,"changeRate":0.16666666666666666,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4710883000,"eps":-0.0179,"marketStatus":"Market Closed","change":0.001,"latestTime":"10-02 16:12:00 AEST","open":0.006,"high":0.007,"low":0.006,"amount":64306,"amplitude":0.166667,"askPrice":0.007,"askSize":3287384,"bidPrice":0.005,"bidSize":6409602,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.006,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":1.170503,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.006,"auctionPrice":0.007,"auctionVolume":299,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921415461}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":1.170503,"shares":4710883000,"dividePrice":0,"high":0.007,"amplitude":0.166667,"preClose":0.006,"low":0.006,"week52Low":0.006,"pbRate":"1.34","psRate":"2.44","week52High":0.04,"institutionHeld":0,"latestPrice":0.007,"committee":0.321978,"eps":-0.0179,"divideRate":0,"volume":10717667,"delay":0,"ttmEps":-0.0179,"open":0.006,"prevYearClose":0.025,"prevWeekClose":0.008,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.008,"twentyDayClose":0.009,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660101432","title":"Radiopharm Theranostics to Meet With US FDA on Phase 3 Brain Metastases Diagnosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101432","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101432?lang=en_us&edition=fundamental","pubTime":"2026-08-17 11:33","pubTimestamp":1786937616,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  will meet with the US Food and Drug Administration  on Oct. 1 to seek alignment on the design of a phase 3 trial to evaluate its RAD101 imaging agent in patients with suspected recurrence of brain metastases following radiotherapy, according to a Monday filing with the Australian bourse.The meeting will focus on the trial's design criteria, including the number of patients to be enrolled and the primary and secondary endpoints, per the filing.The FDA will also review data from a phase 2b trial of RAD 101, which showed 93% concordance between MRI and PET imaging of brain metastases in the targeted patient population, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","RAD.AU","LABU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103689","title":"Radiopharm Theranostics Ltd-Rad to Meet with US FDA to Align on Rad 101 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103689?lang=en_us&edition=fundamental","pubTime":"2026-08-17 07:02","pubTimestamp":1786921352,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nTUE7QS9KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659548111","title":"Radiopharm Theranostics Shareholders Vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari Director SPP Allocations at Sept. 11 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2659548111","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659548111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:05","pubTimestamp":1786622701,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics shareholders vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari director SPP allocations at Sept. 11 meetingRadiopharm Theranostics shareholders vote Sept. 11, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLb5WwMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657566431","title":"Radiopharm Theranostics Ltd-Share Purchase Plan - NOW Open","url":"https://stock-news.laohu8.com/highlight/detail?id=2657566431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657566431?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:38","pubTimestamp":1786059496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUEQ4HGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686203","title":"Radiopharm Theranostics - Plans to Initiate Phase 3 Registrational Trial of Rad 101 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686203?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:02","pubTimestamp":1785495776,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368915","title":"Radiopharm Theranostics - Closing Cash at End of Quarter $4.10 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368915?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:02","pubTimestamp":1785495776,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686303","title":"Radiopharm Theranostics Plans Phase 3 Registrational Trial of Imaging Agent Rad101 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686303","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686303?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:01","pubTimestamp":1785495703,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics plans Phase 3 registrational trial of imaging agent RAD101 in Q4 2026Radiopharm Theranostics reported Phase 2b results for imaging agent RAD 101 in recurrent brain metastases, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDLbx6scR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","RAD.AU","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","BK7067","IE00BN0W2W23.USD","BCDF","SG9999014021.USD","BK4585","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368936","title":"Press Release: Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368936?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:00","pubTimestamp":1785495600,"startTime":"0","endTime":"0","summary":"endpoint, with 93% of patients treated with RAD 101 achieving concordance. with MRI imaging. Additionally, an interim analysis of 14 patients from. -- The Company anticipates the initiation of a Phase 3, multi-center,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4139","IDNA","NVIB","GDOC","MEDX","IE0009354923.USD","BK7067","RAD.AU","RADX","BK4183","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655866708","title":"Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2655866708","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655866708?lang=en_us&edition=fundamental","pubTime":"2026-07-29 00:00","pubTimestamp":1785254401,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics announces extraordinary general meeting for shareholder approvalsRadiopharm Theranostics will hold an extraordinary general meeting in Australia on about Sept. 11, 2026.Shareho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL3Jkm6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654301951","title":"Radiopharm Theranostics Prices Unregistered Warrants in Private Placement at Us$3.79 Per ADS","url":"https://stock-news.laohu8.com/highlight/detail?id=2654301951","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654301951?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:06","pubTimestamp":1785146819,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics prices unregistered warrants in private placement at US$3.79 per ADSRadiopharm Theranostics priced a concurrent private placement of unregistered warrants to buy 1,281,646 ADSs","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLvvvlB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654349067","title":"Radiopharm Theranostics Secures Nearly AU$13 Million Through Dual Institutional Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2654349067","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654349067?lang=en_us&edition=fundamental","pubTime":"2026-07-27 06:02","pubTimestamp":1785103327,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) secured firm commitments to raise around AU$12.5 million through a two-part institutional capital raising, comprising an Australian placement and a US direct register","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067","ADS.AU","BK7016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089441","title":"Radiopharm Theranostics Announces Concurrent Us$4.1 Million Registered Direct Offering and up to Additional A$12.7 (us$8.9) Million Australian Placement and Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653089441?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:15","pubTimestamp":1784891700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA2BTVJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089553","title":"Radiopharm Theranostics Calls Extraordinary Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089553","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653089553?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:01","pubTimestamp":1784890909,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics calls extraordinary shareholder meetingRadiopharm Theranostics will hold an extraordinary general meeting in Australia on Sept. 11, 2026.Shareholders will vote on approvals tie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL26pT5p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653704554","title":"Radiopharm Theranostics - Receives Firm Commitments for A$12.5 Mln Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704554?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:21","pubTimestamp":1784877673,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nFWN43P1FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754780","title":"Radiopharm Theranostics - no Dose-limiting Toxicities Observed with Rad204 in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754780?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA3MMWNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754735","title":"Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of Rad204 in Patients with Advanced Solid Tumors Post-immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754735?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA3MMWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754924","title":"Radiopharm Theranostics Partners with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754924","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754924?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718053,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialRadiopharm Theranostics partnered with Siemens Healthineers to manufacture and di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL3qgNlv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK7067","BK4588","RAD.AU","BK4112","LU2095319765.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754608","title":"Radiopharm Theranostics Announces Positive Phase 2B Trial Results of Rad 101 for Diagnosis of Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754608?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA39F6Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653544827","title":"Radiopharm Theranostics - Rad101 Shows Preliminary 86% Sensitivity in Six-month Follow-up; Specificity Data Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653544827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653544827?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA39F6Y1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653364567","title":"Radiopharm Theranostics' Phase 2b Trial of Brain Metastases Diagnosis Agent Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2653364567","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653364567?lang=en_us&edition=fundamental","pubTime":"2026-07-22 13:09","pubTimestamp":1784696971,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said a phase 2b trial of RAD101 in participants with suspected recurrence of brain metastases after radiotherapy met its primary endpoint, according to a Wednesday filing with the Australian bourse.The analysis of the imaging data for all assessed lesions showed 93% concordance between magnetic resonance imaging and PET scans of brain metastases, per the filing.Meanwhile, 14 patients with evaluable six-month data showed preliminary sensitivity of 86%, a gauge of an imaging test's ability to correctly identify patients with disease.The results also showed \"substantial and selective tumor uptake of RAD101,\" supporting its progression into an intended registrational phase 3 program, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":71,"code":"91000000","status":"200"}]}}